A phase 3 trial of L-Glutamine in sickle cell disease

A. Kumar Guddati; Kota Vamsi Kota

doi:10.1056/NEJMc1811050

A phase 3 trial of L-Glutamine in sickle cell disease

A. Kumar Guddati, Kota Vamsi Kota

Pulmonary Disease

Research output: Contribution to journal › Letter › peer-review

19 Scopus citations

Original language	English (US)
Pages (from-to)	1879
Number of pages	1
Journal	New England Journal of Medicine
Volume	379
Issue number	19
DOIs	https://doi.org/10.1056/NEJMc1811050
State	Published - Nov 8 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc1811050

Cite this

@article{bb86ede5a7694f17ad20ec73ff23a5d0,

title = "A phase 3 trial of L-Glutamine in sickle cell disease",

author = "{Kumar Guddati}, A. and {Vamsi Kota}, Kota",

note = "Funding Information: Dr. Stefan Anker reports having received consulting fees from Bayer, Boehringer Ingelheim, Novartis, Servier, and Vifor and grant support from Abbott Vascular and Vifor and having held equity interest in Actimed Therapeutics; and Dr. Markus Anker having received personal fees from Servier. No other potential conflict of interest relevant to this letter was reported.",

year = "2018",

month = nov,

day = "8",

doi = "10.1056/NEJMc1811050",

language = "English (US)",

volume = "379",

pages = "1879",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

TY - JOUR

T1 - A phase 3 trial of L-Glutamine in sickle cell disease

AU - Kumar Guddati, A.

AU - Vamsi Kota, Kota

N1 - Funding Information: Dr. Stefan Anker reports having received consulting fees from Bayer, Boehringer Ingelheim, Novartis, Servier, and Vifor and grant support from Abbott Vascular and Vifor and having held equity interest in Actimed Therapeutics; and Dr. Markus Anker having received personal fees from Servier. No other potential conflict of interest relevant to this letter was reported.

PY - 2018/11/8

Y1 - 2018/11/8

UR - http://www.scopus.com/inward/record.url?scp=85056423729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056423729&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1811050

DO - 10.1056/NEJMc1811050

M3 - Letter

C2 - 30406979

AN - SCOPUS:85056423729

SN - 0028-4793

VL - 379

SP - 1879

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 19

ER -

A phase 3 trial of L-Glutamine in sickle cell disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this